The Comprehensive Guide to Epirubicin 50mg Injection In the field of oncology, Epirubicin 50mg Injection is a cornerstone of chemotherapy regimens used to treat a broad spectrum of malignancies. As a leading pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital anthracycline medication reaches healthcare facilities in London, New York, Sydney, Johannesburg, and across the globe with full regulatory compliance. Product Specifications Brand Name: Ernest-Oncology (Epirubicin Hydrochloride) Strength: 50 mg / 25 mL Dosage Form: Solution for Injection Primary Indication: Treatment of breast, gastric, ovarian, and lung cancers, as well as lymphomas Storage: Store at 2°C to 8°C (36°F to 46°F) and protect from light Mechanism of Action: How It Works DNA Intercalation: It binds to DNA by sliding between base pairs, which inhibits the synthesis of new DNA and RNA. Topoisomerase II Inhibition: Epirubicin triggers DNA cleavage by topoisomerase II, leading to irreversible DNA strand breakage and cell death. Free Radical Generation: The drug generates cytotoxic free radicals that cause oxidative damage to cell membranes, mitochondria, and DNA. Cell Cycle Impact: While active in all phases, its maximal killing effect occurs during the S and G2 phases of the cell cycle. Therapeutic Indications & Administration Adjuvant Therapy: Often used after surgery to eradicate micrometastases and reduce the risk of cancer recurrence, particularly in breast cancer. Intravesical Use: It may be instilled directly into the bladder to treat or prevent the recurrence of superficial bladder cancer. Intravenous Administration: Must be administered only into a vein by a qualified healthcare professional, often via the tubing of a free-running saline infusion to minimize tissue damage. Dosing: Standard adult dosages range from 60–90 mg/m² or higher for specific lung cancer protocols, typically repeated every 21–28 days. Clinical Side Effects & Safety Cardiotoxicity: Epirubicin carries a risk of serious heart problems, including heart failure, which can occur during or even years after treatment. Bone Marrow Suppression: Significant decreases in white blood cells (neutropenia), red blood cells, and platelets are common, increasing the risk of infection and bleeding. Infusion Site Reactions: Extravasation (leaking into surrounding tissue) can cause severe tissue damage, pain, and blistering. Secondary Malignancies: There is an increased risk of developing secondary leukemia. Common Effects: Nausea, vomiting, hair loss, and a harmless red discoloration of urine for 1–2 days after the dose. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective oncology solutions to meet the needs of both private and public healthcare providers. USA: Delivering bulk supply solutions that meet stringent quality and documentation benchmarks for patient care. Australia: Facilitating access to essential medications through established “Special Access Scheme“ (SAS) supply chains. South Africa: Bridging critical gaps in the oncology market with reliable, high-quality pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us
